^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CVGBM

    i
    Other names: CVGBM, CV09050101
    Associations

    News

    Trials
    Company:
    CureVac
    Drug class:
    Immunostimulant, Tumor-associated antigen inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, CureVac | Recruiting --> Active, not recruiting | N=54 --> 16
    Enrollment closed • Enrollment change
    |
    IDH wild-type
    |
    CVGBM
    7ms
    TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (EANO 2023)
    In addition to the primary safety objectives, secondary objectives of efficacy (progression-free survival, overall survival) and patient-reported quality of life outcomes will be assessed. Trial sponsor: CureVac SE, Germany.
    Clinical • P1 data • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
    |
    TMB-L • HLA-A*02:01 • HLA-A*02 • IDH wild-type
    |
    CVGBM
    10ms
    Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma (clinicaltrials.gov)
    P1, N=54, Recruiting, CureVac
    New P1 trial
    |
    IDH wild-type
    |
    CVGBM